Back to Search
Start Over
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
- Source :
- Transplantation and Cellular Therapy; February 2021, Vol. 27 Issue: 2 p153-162, 10p
- Publication Year :
- 2021
-
Abstract
- •Quizartinib enabled more patients to undergo hematopoietic stem cell transplantation (HSCT) versus chemotherapy.•Continuation of quizartinib after HSCT was tolerable, with no new safety signals.•Quizartinib before and after HSCT may confer clinical benefits in relapsed/refractory FLT3-ITD acute myelogenous leukemia.
Details
- Language :
- English
- ISSN :
- 26666375 and 26666367
- Volume :
- 27
- Issue :
- 2
- Database :
- Supplemental Index
- Journal :
- Transplantation and Cellular Therapy
- Publication Type :
- Periodical
- Accession number :
- ejs55431739
- Full Text :
- https://doi.org/10.1016/j.bbmt.2020.09.036